Literature DB >> 33109529

Survival Following Traumatic Brain Injury in Drosophila Is Increased by Heterozygosity for a Mutation of the NF-κB Innate Immune Response Transcription Factor Relish.

Laura C Swanson1,2, Edna A Trujillo3,4, Gene H Thiede1, Rebeccah J Katzenberger1, Evgenia Shishkova4,5, Joshua J Coon3,4,5,6, Barry Ganetzky7, David A Wassarman8.   

Abstract

Traumatic brain injury (TBI) pathologies are caused by primary and secondary injuries. Primary injuries result from physical damage to the brain, and secondary injuries arise from cellular responses to primary injuries. A characteristic cellular response is sustained activation of inflammatory pathways commonly mediated by nuclear factor-κB (NF-κB) transcription factors. Using a Drosophila melanogaster TBI model, we previously found that the main proximal transcriptional response to primary injuries is triggered by activation of Toll and Imd innate immune response pathways that engage NF-κB factors Dif and Relish (Rel), respectively. Here, we found by mass spectrometry that Rel protein level increased in fly heads at 4-8 hr after TBI. To investigate the necessity of Rel for secondary injuries, we generated a null allele, Rel del , by CRISPR/Cas9 editing. When heterozygous but not homozygous, the Rel del mutation reduced mortality at 24 hr after TBI and increased the lifespan of injured flies. Additionally, the effect of heterozygosity for Rel del on mortality was modulated by genetic background and diet. To identify genes that facilitate effects of Rel del on TBI outcomes, we compared genome-wide mRNA expression profiles of uninjured and injured +/+, +/Rel del , and Rel del /Rel del flies at 4 hr following TBI. Only a few genes changed expression more than twofold in +/Rel del flies relative to +/+ and Rel del /Rel del flies, and they were not canonical innate immune response genes. Therefore, Rel is necessary for TBI-induced secondary injuries but in complex ways involving Rel gene dose, genetic background, diet, and possibly small changes in expression of innate immune response genes.
Copyright © 2020 by the Genetics Society of America.

Entities:  

Keywords:  Drosophila melanogaster; gene expression; innate immunity; proteomics; traumatic brain injury

Mesh:

Substances:

Year:  2020        PMID: 33109529      PMCID: PMC7768241          DOI: 10.1534/genetics.120.303776

Source DB:  PubMed          Journal:  Genetics        ISSN: 0016-6731            Impact factor:   4.562


  118 in total

1.  Genes encoding cuticular proteins are components of the Nimrod gene cluster in Drosophila.

Authors:  Gyöngyi Cinege; János Zsámboki; Maite Vidal-Quadras; Anne Uv; Gábor Csordás; Viktor Honti; Erika Gábor; Zoltán Hegedűs; Gergely I B Varga; Attila L Kovács; Gábor Juhász; Michael J Williams; István Andó; Éva Kurucz
Journal:  Insect Biochem Mol Biol       Date:  2017-06-17       Impact factor: 4.714

2.  Relish, a central factor in the control of humoral but not cellular immunity in Drosophila.

Authors:  M Hedengren; B Asling; M S Dushay; I Ando; S Ekengren; M Wihlborg; D Hultmark
Journal:  Mol Cell       Date:  1999-11       Impact factor: 17.970

3.  IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury.

Authors:  André Luiz Dalla Libera; Andrea Regner; Juliana de Paoli; Leonara Centenaro; Tatiane Tolazzi Martins; Daniel Simon
Journal:  Brain Inj       Date:  2011-02-11       Impact factor: 2.311

Review 4.  Peptidoglycan recognition proteins in Drosophila immunity.

Authors:  Shoichiro Kurata
Journal:  Dev Comp Immunol       Date:  2013-06-22       Impact factor: 3.636

5.  Long-term neurologic outcomes after traumatic brain injury.

Authors:  Jeffrey J Bazarian; Ibolja Cernak; Linda Noble-Haeusslein; Samuel Potolicchio; Nancy Temkin
Journal:  J Head Trauma Rehabil       Date:  2009 Nov-Dec       Impact factor: 2.710

Review 6.  Cellular immune defenses of Drosophila melanogaster.

Authors:  Brendon Parsons; Edan Foley
Journal:  Dev Comp Immunol       Date:  2015-12-31       Impact factor: 3.636

Review 7.  The Drosophila IMD pathway in the activation of the humoral immune response.

Authors:  Anni Kleino; Neal Silverman
Journal:  Dev Comp Immunol       Date:  2013-05-27       Impact factor: 3.636

Review 8.  Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury.

Authors:  Clifford L Eastman; Raimondo D'Ambrosio; Thota Ganesh
Journal:  Neuropharmacology       Date:  2019-12-06       Impact factor: 5.250

9.  Smooth, an hnRNP-L Homolog, Might Decrease Mitochondrial Metabolism by Post-Transcriptional Regulation of Isocitrate Dehydrogenase (Idh) and Other Metabolic Genes in the Sub-Acute Phase of Traumatic Brain Injury.

Authors:  Arko Sen; Katherine Gurdziel; Jenney Liu; Wen Qu; Oluwademi O Nuga; Rayanne B Burl; Maik Hüttemann; Roger Pique-Regi; Douglas M Ruden
Journal:  Front Genet       Date:  2017-11-15       Impact factor: 4.772

10.  Mammalian Models of Traumatic Brain Injury and a Place for Drosophila in TBI Research.

Authors:  Ekta J Shah; Katherine Gurdziel; Douglas M Ruden
Journal:  Front Neurosci       Date:  2019-04-26       Impact factor: 4.677

View more
  3 in total

Review 1.  Drosophila as a model to explore secondary injury cascades after traumatic brain injury.

Authors:  Lori M Buhlman; Gokul Krishna; T Bucky Jones; Theresa Currier Thomas
Journal:  Biomed Pharmacother       Date:  2021-08-27       Impact factor: 7.419

2.  Dietary restriction ameliorates TBI-induced phenotypes in Drosophila melanogaster.

Authors:  Rebecca Delventhal; Emily R Wooder; Maylis Basturk; Mohima Sattar; Jonathan Lai; Danielle Bolton; Gayathri Muthukumar; Matthew Ulgherait; Mimi M Shirasu-Hiza
Journal:  Sci Rep       Date:  2022-06-09       Impact factor: 4.996

3.  Ketogenic diet reduces early mortality following traumatic brain injury in Drosophila via the PPARγ ortholog Eip75B.

Authors:  Joseph Blommer; Megan C Fischer; Athena R Olszewski; Rebeccah J Katzenberger; Barry Ganetzky; David A Wassarman
Journal:  PLoS One       Date:  2021-10-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.